ASCVD Articles

Articles
Impact of the 2021 ESC Prevention Guideline’s stepwise approach for cardiovascular risk factor treatment in patients with established ASCVD
Holtrop J, Bhatt DL, Ray KK, et al.
Journal:
Eur J Prev Cardiol

First published: February 7, 2024 DOI: 10.1093/eurjpc/zwae038
View
- Share
Articles
Universal Risk Prediction for Individuals With and Without Atherosclerotic Cardiovascular Disease
Mok Y, Dardari Z, Sang Y, et al.
Journal:
J Am Coll Cardiol

First published: February 6, 2024 DOI: 10.1016/j.jacc.2023.11.028
View
- Share
Articles
Bempedoic acid: new evidence and recommendations on use
Paponja K, Pećin I, Reiner Ž, et al.
Journal:
Curr Opin Lipidol

First published: February 1, 2024 DOI: 10.1097/MOL.0000000000000911
View
- Share
Articles
Obesity and atherosclerotic cardiovascular disease in adults with heterozygous familial hypercholesterolemia: An analysis from HELLAS-FH registry
Barkas F, Rizos CV, Liamis G, et al.
Journal:
J Clin Lipidol

First published: January 24, 2024 DOI: 10.1016/j.jacl.2024.01.005
View
- Share
Articles
World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease: 2023 Update
Laranjo L, Lanas F, Sun MC, et al.
Journal:
Glob Heart

First published: January 22, 2024 DOI: 10.5334/gh.1278
View
- Share
Articles
Trends in prevalence, risk factor control and medications in atherosclerotic cardiovascular disease among US Adults, 1999-2018
Zhang X, Chen Z, Fang A, et al.
Journal:
Am J Prev Cardiol

First published: January 20, 2024 DOI: 10.1016/j.ajpc.2024.100634
View
- Share
Articles
The year in cardiovascular medicine 2023: the top 10 papers in dyslipidaemias
Tokgözoğlu L, Orringer C, Catapano AL
Journal:
Eur Heart J

First published: December 28, 2023 DOI: 10.1093/eurheartj/ehad837
View
- Share
Articles
Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments
Kastelein JJP, Hsieh A, Dicklin MR, et al.
Journal:
Curr Atheroscler Rep

First published: December 22, 2023 DOI: 10.1007/s11883-023-01184-1
View
- Share
Articles
Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials
Wright RS, Koenig W, Landmesser U, et al.
Journal:
J Am Coll Cardiol

First published: December 12, 2023 DOI: 10.1016/j.jacc.2023.10.007
View
- Share
Articles
Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review
McClintick DJ, Giugliano RP
Journal:
Curr Opin Lipidol

First published: December 1, 2023 DOI: 10.1097/MOL.0000000000000897
View
- Share
Articles
National Trends in Racial and Ethnic Disparities in Use of Recommended Therapies in Adults with Atherosclerotic Cardiovascular Disease, 1999-2020
Lu Y, Liu Y, Dhingra LS, et al.
Journal:
JAMA Netw Open

First published: December 1, 2023 DOI: 10.1001/jamanetworkopen.2023.45964
View
- Share
Articles
Atherosclerotic Cardiovascular Events in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Retrospective Cohort Study
Tan S, Spear E, Sane N, et al.
Journal:
Heart Lung Circ

First published: December 1, 2023 DOI: 10.1016/j.hlc.2023.10.008
View
- Share

1 2 3 … 15

ASCVD Articles

Articles

Impact of the 2021 ESC Prevention Guideline’s stepwise approach for cardiovascular risk factor treatment in patients with established ASCVD

Holtrop J, Bhatt DL, Ray KK, et al.

Articles

Universal Risk Prediction for Individuals With and Without Atherosclerotic Cardiovascular Disease

Mok Y, Dardari Z, Sang Y, et al.

Articles

Bempedoic acid: new evidence and recommendations on use

Paponja K, Pećin I, Reiner Ž, et al.

Articles

Obesity and atherosclerotic cardiovascular disease in adults with heterozygous familial hypercholesterolemia: An analysis from HELLAS-FH registry

Barkas F, Rizos CV, Liamis G, et al.

Articles

World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease: 2023 Update

Laranjo L, Lanas F, Sun MC, et al.

Articles

Trends in prevalence, risk factor control and medications in atherosclerotic cardiovascular disease among US Adults, 1999-2018

Zhang X, Chen Z, Fang A, et al.

Articles

The year in cardiovascular medicine 2023: the top 10 papers in dyslipidaemias

Tokgözoğlu L, Orringer C, Catapano AL

Articles

Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments

Kastelein JJP, Hsieh A, Dicklin MR, et al.

Articles

Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials

Wright RS, Koenig W, Landmesser U, et al.

Articles

Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review

McClintick DJ, Giugliano RP

Articles

National Trends in Racial and Ethnic Disparities in Use of Recommended Therapies in Adults with Atherosclerotic Cardiovascular Disease, 1999-2020

Lu Y, Liu Y, Dhingra LS, et al.

Articles

Atherosclerotic Cardiovascular Events in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Retrospective Cohort Study

Tan S, Spear E, Sane N, et al.

Articles

Impact of the 2021 ESC Prevention Guideline’s stepwise approach for cardiovascular risk factor treatment in patients with established ASCVD

Holtrop J, Bhatt DL, Ray KK, et al.

Share

Articles

Universal Risk Prediction for Individuals With and Without Atherosclerotic Cardiovascular Disease

Mok Y, Dardari Z, Sang Y, et al.

Share

Articles

Bempedoic acid: new evidence and recommendations on use

Paponja K, Pećin I, Reiner Ž, et al.

Share

Articles

Obesity and atherosclerotic cardiovascular disease in adults with heterozygous familial hypercholesterolemia: An analysis from HELLAS-FH registry

Barkas F, Rizos CV, Liamis G, et al.

Share

Articles

World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease: 2023 Update

Laranjo L, Lanas F, Sun MC, et al.

Share

Articles

Trends in prevalence, risk factor control and medications in atherosclerotic cardiovascular disease among US Adults, 1999-2018

Zhang X, Chen Z, Fang A, et al.

Share

Articles

The year in cardiovascular medicine 2023: the top 10 papers in dyslipidaemias

Tokgözoğlu L, Orringer C, Catapano AL

Share

Articles

Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments

Kastelein JJP, Hsieh A, Dicklin MR, et al.

Share

Articles

Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials

Wright RS, Koenig W, Landmesser U, et al.

Share

Articles

Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review

McClintick DJ, Giugliano RP

Share

Articles

National Trends in Racial and Ethnic Disparities in Use of Recommended Therapies in Adults with Atherosclerotic Cardiovascular Disease, 1999-2020

Lu Y, Liu Y, Dhingra LS, et al.

Share

Articles

Atherosclerotic Cardiovascular Events in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Retrospective Cohort Study

Tan S, Spear E, Sane N, et al.

Share